You are here

Article Text

Article menu
Download PDFPDF
Commentary
Does it all ADA up? Adalimumab for ulcerative colitis

https://doi.org/10.1136/gut.2010.233403

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Linked articles 235507, 221127.

    • Competing interests ST has acted as an advisor to, lecturer for or been in receipt of unrestricted educational grants from Abbott Pharmaceuticals, Asahi, Elan, Ferring Pharmaceuticals, Genentech, Genzyme, MSD, Novartis, NovoNordisk, Shire, takeda, Tillotts, UCB, Vertex, Vifor and Warner Chilcott.

    • Provenance and peer review Commissioned; not externally peer reviewed.

    Linked Articles